Long-Term Care Facilities, Vaccine and Virus

Walgreens Statement Regarding FDA Emergency Use Authorization of COVID-19 Vaccine

The Pharma Data

DECEMBER 11, 2020

We will be collaborating with nearly 35,000 skilled nursing and assisted living facilities nationwide that have selected Walgreens as their vaccine provider. Our purpose – to champion the health and wellbeing of every community in America – has never been more clear or critical,” said John Standley, Walgreens president.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Pharmacy Assisted Living

ECDC and EMA highlight considerations for additional and booster doses.

The Pharma Data

SEPTEMBER 6, 2021

Based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population, according to a technical report issued by the European Centre for Disease Prevention and Control (ECDC). EMA will also be assessing data on booster doses.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Immune Response Virus

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

The Pharma Data

SEPTEMBER 18, 2020

This week Pharma IQ looks at how the pharma industry is expanding its vaccine manufacturing and testing protocols to ensure the deadly Covid-19 outbreak yields in its spread around the globe. . BioNTech acquires Novartis GMP manufacturing site to expand Covid-19 vaccine production.

Vaccine

Vaccine Long-Term Care Facilities Clinical Supply Laboratories

FDA Advisory Panel Says Yes to Pfizer’s COVID Vaccine

The Pharma Data

DECEMBER 10, 2020

Food and Drug Administration advisory panel recommended on Thursday that the agency authorize the emergency use of Pfizer’s coronavirus vaccine, clearing the way for a national campaign to inoculate enough Americans to stop the spread of COVID-19. The FDA is expected to authorize the vaccine’s use within days, the Post reported.

Vaccine

Vaccine FDA Long-Term Care Facilities Hospitals

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

The Pharma Data

DECEMBER 19, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the U.S. 11 ACIP members voted in favor of the vaccine and 0 members voted against. Healthcare workers have been on the front lines of the fight against the virus and are an inspiration to us all.

Vaccine

Vaccine Long-Term Care Facilities FDA Licensing

Britain Approves Emergency Use of Pfizer’s COVID Vaccine

The Pharma Data

DECEMBER 2, 2020

2, 2020 – Britain became the first Western country to allow emergency use of a coronavirus vaccine on Wednesday, after approving Pfizer’s candidate in the race to inoculate millions of people around the globe. But there are daunting obstacles to the vaccine’s delivery to the masses. WEDNESDAY, Dec.

Vaccine

Vaccine Long-Term Care Facilities Hospitals Nurses

Biden Will Ask Americans to Wear Masks for 100 Days

The Pharma Data

DECEMBER 4, 2020

And I think we’ll see a significant reduction” in the virus, Biden told CNN. Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. And it has stirred up a global debate about how to balance the dire need for a vaccine against the importance of looking for clear signs that a vaccine is safe.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Nurses Hospitals

CDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, Deaths

The Pharma Data

DECEMBER 3, 2020

Though coronavirus cases have exploded recently, with new infections topping 1 million a week, a far smaller proportion of people who get the virus now are dying from it. ” Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. But there are daunting obstacles to the vaccine’s delivery to the masses.

Hospitals

Hospitals Long-Term Care Facilities Vaccine Nurses

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. However, sites of care should not dispose of bamlanivimab supply; instead, they should order etesevimab to pair with it. All sites in the U.S. In the U.S.,

Treatment

Treatment Hospitals Long-Term Care Facilities Virus

Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

The Pharma Data

APRIL 14, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Government

Government Long-Term Care Facilities Hospitals Treatment

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

The Pharma Data

FEBRUARY 1, 2021

1, 2021 — As America’s vaccination campaign begins to gain momentum, a promising sign has emerged: Federal data shows that coronavirus cases in nursing homes have declined over the past four weeks. Since the rollout began, nursing home residents and staff have been prioritized as among the first groups to get the vaccine.

Nurses

Nurses Vaccine Long-Term Care Facilities Virus

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

The Pharma Data

MAY 4, 2021

. “ Lilly ‘s action provides both important new options and potential resources for countries’ health and regulatory leaders to consider for the care of COVID-19 patients, and Direct Relief will of course move with urgency upon receiving any such requests.” Ricks , Lilly chairman and CEO.

Therapies

Therapies Hospitals FDA Approval Long-Term Care Facilities

Study Suggests Link Between Sleep Supplement and COVID-19

The Pharma Data

DECEMBER 21, 2020

However, there are two vaccines that have been authorized in the U.S. Both vaccines require two doses, according to USA Today. Each of the vaccines targets the “spike protein” found on the surface of the virus that causes the illness. This typically allows the virus to attach itself to host cells and infect them.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Virus Clinical Trials

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The PROVENT trial will give us more clarity in this patient population.

Trials

Trials Long-Term Care Facilities Virus Government

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

JANUARY 24, 2021

Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. Transgene and BioInvent received approval from France’s national regulatory agency to begin a Phase I/IIa trial of Vaccinia virus BT-001 in solid tumors. Read on to see.

Long-Term Care Facilities

Long-Term Care Facilities Trials Virus Clinical Trials

Lilly Announces Agreement with U.S. government to Supply 300,000 vials of Investigational Neutralizing Antibody Bamlanivimab (LY-CoV555) in an Effort to Fight COVID-19

The Pharma Data

OCTOBER 28, 2020

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Government

Government Long-Term Care Facilities Hospitals Therapies

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

The Pharma Data

JANUARY 26, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Hospitals

Hospitals Treatment Long-Term Care Facilities Trials

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

The Pharma Data

NOVEMBER 9, 2020

. “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,

Treatment

Treatment FDA Hospitals Long-Term Care Facilities

Biden Says He Will Release All Vaccine Doses After Taking Office

The Pharma Data

JANUARY 8, 2021

8, 2021 — President-elect Joe Biden plans to release nearly all available doses of COVID-19 vaccine when he takes office, reversing the Trump administration’s strategy of holding back half the supply to ensure second doses are available. We are in a race with this virus, so anything that speeds vaccination should be applauded.”

Vaccine

Vaccine Long-Term Care Facilities Hospitals FDA

Health Highlights: Dec. 14, 2020

The Pharma Data

DECEMBER 14, 2020

Below are newsworthy items compiled by HealthDay staff: No Early Vaccination of White House Officials. White House officials will no longer be among the first Americans to be vaccinated against COVID-19. I am not scheduled to take the vaccine, but look forward to doing so at the appropriate time.” © 2020 HealthDay.

Long-Term Care Facilities

Long-Term Care Facilities Vaccine Nurses Virus

EMA issues advice on Lilly’s bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

The Pharma Data

MARCH 5, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Treatment

Treatment Hospitals Long-Term Care Facilities Therapies

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

The Pharma Data

MARCH 11, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Hospitals

Hospitals Trials Long-Term Care Facilities Treatment

‘Warp Speed’ Officials Say U.S. COVID Vaccine Distribution Too Slow

The Pharma Data

DECEMBER 31, 2020

million doses of the approved Pfizer and Moderna COVID-19 vaccines had been distributed across the United States by Monday morning, just 2.1 That’s far too slow a pace, said one official charged with spearheading the vaccination of Americans. million vaccination tally — compiled by the U.S. . THURSDAY, Dec.

Vaccine

Vaccine Long-Term Care Facilities Virus Hospitals

Drug Discovery Digest

Walgreens Statement Regarding FDA Emergency Use Authorization of COVID-19 Vaccine

ECDC and EMA highlight considerations for additional and booster doses.

Trending Sources

Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…

FDA Advisory Panel Says Yes to Pfizer’s COVID Vaccine

U.S. CDC Advisory Committee on Immunization Practices Recommends Vaccination with Moderna’s COVID-19 Vaccine for Persons 18 Years and Older

Britain Approves Emergency Use of Pfizer’s COVID Vaccine

Biden Will Ask Americans to Wear Masks for 100 Days

CDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, Deaths

bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.

Bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together

Drop in COVID Cases Seen in Nursing Homes as U.S. Vaccine Effort Makes Headway

Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries | Eli Lilly and Company

Study Suggests Link Between Sleep Supplement and COVID-19

Update on AZD7442 STORM CHASER trial in post-exposure prevention of symptomatic COVID-19

Clinical Catch-Up: January 18-22 | BioSpace

Lilly Announces Agreement with U.S. government to Supply 300,000 vials of Investigational Neutralizing Antibody Bamlanivimab (LY-CoV555) in an Effort to Fight COVID-19

New Data Show Treatment with Lilly’s Neutralizing Antibodies Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Together Reduced Risk of COVID-19 Hospitalizations and Death by 70 Percent

Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed COVID-19

Biden Says He Will Release All Vaccine Doses After Taking Office

Health Highlights: Dec. 14, 2020

EMA issues advice on Lilly’s bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19

‘Warp Speed’ Officials Say U.S. COVID Vaccine Distribution Too Slow

Stay Connected